Residual DNA Quantification Kit for Plasmids Plus

Biopharmaceutical products, such as monoclonal antibodies, vaccines, and gene therapies, are often produced using cell culture systems. These systems may involve the use of recombinant bacteria or mammalian cells that harbor plasmids—circular, double-stranded DNA molecules used to introduce and express therapeutic genes. During the production process, cells or cell lysates are processed to extract and purify the desired therapeutic protein or nucleic acid. Inevitably, some host cell DNA, including plasmid DNA, can co-purify with the product. The presence of residual DNA poses potential risks, such as the production of immunogenicity, carcinogenicity, or unintended genetic effects.

The Plasmid Residual DNA Quantification Kit is an important tool to achieve these goals, utilizing advanced molecular techniques to provide accurate, reliable, and regulatory compliant measurements of residual plasmid DNA in biopharmaceutical products. Its ability to accurately measure low levels of residual DNA enables manufacturers to ensure product safety, adhere to regulatory standards, and maintain confidence in their therapeutic products. As biopharmaceutical technology and the regulatory landscape continue to evolve, the importance of accurate residual DNA quantification will remain a cornerstone of product integrity and safety.